All News
Wager question that cemented the winners: @UTMB:
⭐️This monogenic disease can mimic Behcet's & occurs d/t mutat in TNFAIP3.
➡️Haploinsufficiency A20
Congrats to the winners & all contestants, including the top 2 finalists: @MGHrheumatology & @EmoryUniversity!
#ACR21 @RheumNow https://t.co/LZqsBKiPL8
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Anti-NETs antibodies in #COVID.
1️⃣ correlate➖ w/ SpO2/FiO2 ratio (IgG r=-0.17 IgM r=-0.30
2️⃣correlate➕ w/ ⬆️D-dimer (IgG r=0.33 IgM r=0.19
3️⃣ ⬆️ in pts requiring MV
In a study of 328 pts. Probably driving complement activation!
#ACR21 #Abst1430 @RheumNow https://t.co/2MCrLueTzN
Aurelie Najm AurelieRheumo ( View Tweet)
AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0
Dr. Antoni Chan synovialjoints ( View Tweet)
Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment
⭐️no new onset IBD or exacerbation of IBD
⭐️no uveitis, infections, TB
Abs#1342
#ACR21
@RheumNow
https://t.co/x3OmLgInV0
Robert B Chao, MD doctorRBC ( View Tweet)
⭐️ Wanna catch up with the latest news on JAKi safety trials presented at #ACR21? Our @Rheumnow interview with @ErnestChoy1 is out. Link below
https://t.co/zYb4rXcw1x https://t.co/i39xXnfC3Q
Aurelie Najm AurelieRheumo ( View Tweet)
You can <but not as frequently> treat to target in #RheumatoidArthritis with virtual v in person visits. 45 docs in 18 practices comparing in person to virtual. In person wins but not by a large gap! Abst#1448 @dansolomon @RheumNow #ACR21 #ACRBest session today coming up https://t.co/8lcuMW0bwb
Janet Pope Janetbirdope ( View Tweet)
SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
#PJP prophylaxis debate at #lupus hub if on #prednisone + immune suppression. #SLE has ⤴️septra side effects. Don’t know right answer. NNT v NNH is unknown. I don’t use it in #SLE. @RheumNow #ACR21 8M212
Janet Pope Janetbirdope ( View Tweet)
Post-hoc analysis of Deucravacitinib (TYK2i) for tx of PsA showed similar efficacy in pts with and without background csDMARD use.
⭐️>60% w/ background csDMARD use, majority of which was MTX
⭐️no difference in AE
#ACR21
Abs#1352
@RheumNow
https://t.co/nIJT7rNkJP https://t.co/bq0x1Ywguo
Robert B Chao, MD doctorRBC ( View Tweet)
Wonderful interview @KDAO2011 and @alhkim with great learning points on #BCell #Immunology
#ACR21 @RheumNow https://t.co/1292FNZanL
Akhil Sood MD AkhilSoodMD ( View Tweet)
Does #baricitinib affect #fatigue in RA patients?
👉🏼Results from RA-BEAM and RA-BEACON
👉🏼4mg baricitinib significantly reduced fatigue, starting week 16, compared to placebo
👉🏼Effect independent of disease activity in active RA
Abs#1235 #ACR21 @RheumNow
https://t.co/0SKhUKJHd7 https://t.co/R76wc56u6I
Mrinalini Dey DrMiniDey ( View Tweet)
Go @utmbhealth!
Final Round Knowledge Bowl #ACR21 @RheumNow
@UTMBInternalMed #DanielGonzalez #AparnaDas https://t.co/nQRn3s7J21
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abst 1550 #acr21 @RheumNow @bryan_neel rheum pts after covid 19 vaccine: 18.9% reported SEs after the 1st dose,33.1% after 2nd dose. most frequent SEs fever, HA, fatigue & arthromyalgia. All mild&self resolved. Disease flare in 1/180 pts (0.6%) 1st dose 4/118 (3.4%) 2nd dose https://t.co/5AB5CJfYt8
Olga Petryna DrPetryna ( View Tweet)
Do you use #septa in #renal #lupus if on high dose prednisone? @RheumNow #ACR21 8M212 lupus hub
Janet Pope Janetbirdope ( View Tweet)
After that fantastic Plenary III, we need a well-deserved timeout and time for stretching 🙆🏻♂️ 🙆♀️! #wellness #ACR21 #RheumPix #RheumNow https://t.co/krF5tPAxsE
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 Knowledge Bowl - Enjoy the farmer's market!
--> Cauliflower ears, cherries for gout, alfalfa and SLE... and of course anti-OJ myositis
@Rheumnow https://t.co/K8aG1IKYCu
Eric Dein ericdeinmd ( View Tweet)
#SLE study hub re #Lupus nephritis rocks. #Rituximab ⬇️antiDNA but then rebound ⤴️. Thus design of adding #belimumab to Rituximab=Less flares. Love the Hubs. #ACR21 @RheumNow https://t.co/MAhxJdmkWO 10.7326/M21-2078 #ACRBest https://t.co/qWPk5x1ZtM
Janet Pope Janetbirdope ( View Tweet)
Younger age, male gender, geographic region, lower weight and BMI, dactylitis+ or enthesitis+, lower scores Pt-Pain, PtGA, TJC and HAQ-DI were baseline predictors for achieving MDA and DAPSA LDA at Week 56 in UPA treated patients @RheumNow #ACR21 Abst#1348 https://t.co/FSXarBoBM1 https://t.co/UMCjr6eCRm
Dr. Antoni Chan synovialjoints ( View Tweet)
#ACR21 Ab#1029 - Great poster by Dr. Guttmann, IRAD in Summit NJ:
▶️2019 EULAR/ACR SLE criteria vs to 1997 ACR & SLICC
⭐️64% SLE pts: all 3 criteria. 10% only SLICC, 3% '97 ACR, 2% EULAR/ACR
⭐️Simliar gender, racial disparities to prior criteria
@Rheumnow https://t.co/QzG78HJgw5 https://t.co/eyuYhj4Acf
Links:
Eric Dein ericdeinmd ( View Tweet)